Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent

Sunil Shah, Rahul Chib, Sangram Limbaji Raut, Jaclyn Bermudez, Nirupama Sabnis, Divya Duggal, Joseph D. Kimball, Andras G. Lacko, Zygmunt Gryczynski, Ignacy Gryczynski

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Nanoparticles are target-specific drug delivery agents that are increasingly used in cancer therapy to enhance bioavailability and to reduce off target toxicity of anti-cancer agents. Valrubicin is an anti-cancer drug, currently approved only for vesicular bladder cancer treatment because of its poor water solubility. On the other hand, valrubicin carrying reconstituted high density lipoprotein (rHDL) nanoparticles appear ideally suited for extended applications, including systemic cancer chemotherapy. We determined selected fluorescence properties of the free (unencapsulated) drug vs. valrubicin incorporated into rHDL nanoparticles. We have found that upon encapsulation into rHDL nanoparticles the quantum yield of valrubicin fluorescence increased six fold while its fluorescence lifetime increased about 2 fold. Accordingly, these and potassium iodide (KI) quenching data suggest that upon incorporation, valrubicin is localized deep in the interior of the nanoparticle, inside the lipid matrix. Fluorescence anisotropy of the rHDL valrubicin nanoparticles was also found to be high along with extended rotational correlation time. The fluorescence of valrubicin could also be utilized to assess its distribution upon delivery to prostate cancer (PC3) cells. Overall the fluorescence properties of the rHDL: valrubicin complex reveal valuable novel characteristics of this drug delivery vehicle that may be particularly applicable when used in systemic (intravenous) therapy.

Original languageEnglish
Pages (from-to)60-65
Number of pages6
JournalJournal of Photochemistry and Photobiology B: Biology
Volume155
DOIs
StatePublished - 1 Feb 2016

Fingerprint

valrubicin
lipoproteins
HDL Lipoproteins
Nanoparticles
drugs
cancer
fluorescence
nanoparticles
Pharmaceutical Preparations
Fluorescence
delivery
iodides
therapy
potassium iodides
bioavailability
Neoplasms
bladder
chemotherapy
Potassium Iodide
toxicity

Keywords

  • Cancer
  • Confocal imaging
  • Fluorescence spectroscopy
  • Valrubicin
  • rHDL nanoparticles

Cite this

@article{f82ca60780a44a64ae30032811453469,
title = "Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent",
abstract = "Nanoparticles are target-specific drug delivery agents that are increasingly used in cancer therapy to enhance bioavailability and to reduce off target toxicity of anti-cancer agents. Valrubicin is an anti-cancer drug, currently approved only for vesicular bladder cancer treatment because of its poor water solubility. On the other hand, valrubicin carrying reconstituted high density lipoprotein (rHDL) nanoparticles appear ideally suited for extended applications, including systemic cancer chemotherapy. We determined selected fluorescence properties of the free (unencapsulated) drug vs. valrubicin incorporated into rHDL nanoparticles. We have found that upon encapsulation into rHDL nanoparticles the quantum yield of valrubicin fluorescence increased six fold while its fluorescence lifetime increased about 2 fold. Accordingly, these and potassium iodide (KI) quenching data suggest that upon incorporation, valrubicin is localized deep in the interior of the nanoparticle, inside the lipid matrix. Fluorescence anisotropy of the rHDL valrubicin nanoparticles was also found to be high along with extended rotational correlation time. The fluorescence of valrubicin could also be utilized to assess its distribution upon delivery to prostate cancer (PC3) cells. Overall the fluorescence properties of the rHDL: valrubicin complex reveal valuable novel characteristics of this drug delivery vehicle that may be particularly applicable when used in systemic (intravenous) therapy.",
keywords = "Cancer, Confocal imaging, Fluorescence spectroscopy, Valrubicin, rHDL nanoparticles",
author = "Sunil Shah and Rahul Chib and Raut, {Sangram Limbaji} and Jaclyn Bermudez and Nirupama Sabnis and Divya Duggal and Kimball, {Joseph D.} and Lacko, {Andras G.} and Zygmunt Gryczynski and Ignacy Gryczynski",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.jphotobiol.2015.12.007",
language = "English",
volume = "155",
pages = "60--65",
journal = "Journal of Photochemistry and Photobiology, B: Biology",
issn = "1011-1344",
publisher = "Elsevier",

}

Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent. / Shah, Sunil; Chib, Rahul; Raut, Sangram Limbaji; Bermudez, Jaclyn; Sabnis, Nirupama; Duggal, Divya; Kimball, Joseph D.; Lacko, Andras G.; Gryczynski, Zygmunt; Gryczynski, Ignacy.

In: Journal of Photochemistry and Photobiology B: Biology, Vol. 155, 01.02.2016, p. 60-65.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent

AU - Shah, Sunil

AU - Chib, Rahul

AU - Raut, Sangram Limbaji

AU - Bermudez, Jaclyn

AU - Sabnis, Nirupama

AU - Duggal, Divya

AU - Kimball, Joseph D.

AU - Lacko, Andras G.

AU - Gryczynski, Zygmunt

AU - Gryczynski, Ignacy

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Nanoparticles are target-specific drug delivery agents that are increasingly used in cancer therapy to enhance bioavailability and to reduce off target toxicity of anti-cancer agents. Valrubicin is an anti-cancer drug, currently approved only for vesicular bladder cancer treatment because of its poor water solubility. On the other hand, valrubicin carrying reconstituted high density lipoprotein (rHDL) nanoparticles appear ideally suited for extended applications, including systemic cancer chemotherapy. We determined selected fluorescence properties of the free (unencapsulated) drug vs. valrubicin incorporated into rHDL nanoparticles. We have found that upon encapsulation into rHDL nanoparticles the quantum yield of valrubicin fluorescence increased six fold while its fluorescence lifetime increased about 2 fold. Accordingly, these and potassium iodide (KI) quenching data suggest that upon incorporation, valrubicin is localized deep in the interior of the nanoparticle, inside the lipid matrix. Fluorescence anisotropy of the rHDL valrubicin nanoparticles was also found to be high along with extended rotational correlation time. The fluorescence of valrubicin could also be utilized to assess its distribution upon delivery to prostate cancer (PC3) cells. Overall the fluorescence properties of the rHDL: valrubicin complex reveal valuable novel characteristics of this drug delivery vehicle that may be particularly applicable when used in systemic (intravenous) therapy.

AB - Nanoparticles are target-specific drug delivery agents that are increasingly used in cancer therapy to enhance bioavailability and to reduce off target toxicity of anti-cancer agents. Valrubicin is an anti-cancer drug, currently approved only for vesicular bladder cancer treatment because of its poor water solubility. On the other hand, valrubicin carrying reconstituted high density lipoprotein (rHDL) nanoparticles appear ideally suited for extended applications, including systemic cancer chemotherapy. We determined selected fluorescence properties of the free (unencapsulated) drug vs. valrubicin incorporated into rHDL nanoparticles. We have found that upon encapsulation into rHDL nanoparticles the quantum yield of valrubicin fluorescence increased six fold while its fluorescence lifetime increased about 2 fold. Accordingly, these and potassium iodide (KI) quenching data suggest that upon incorporation, valrubicin is localized deep in the interior of the nanoparticle, inside the lipid matrix. Fluorescence anisotropy of the rHDL valrubicin nanoparticles was also found to be high along with extended rotational correlation time. The fluorescence of valrubicin could also be utilized to assess its distribution upon delivery to prostate cancer (PC3) cells. Overall the fluorescence properties of the rHDL: valrubicin complex reveal valuable novel characteristics of this drug delivery vehicle that may be particularly applicable when used in systemic (intravenous) therapy.

KW - Cancer

KW - Confocal imaging

KW - Fluorescence spectroscopy

KW - Valrubicin

KW - rHDL nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84951844795&partnerID=8YFLogxK

U2 - 10.1016/j.jphotobiol.2015.12.007

DO - 10.1016/j.jphotobiol.2015.12.007

M3 - Article

VL - 155

SP - 60

EP - 65

JO - Journal of Photochemistry and Photobiology, B: Biology

JF - Journal of Photochemistry and Photobiology, B: Biology

SN - 1011-1344

ER -